Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 5

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 5
---
 selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before deciding to invest in our Ordinary Shares, you should read this entire prospectus carefully, including the sections of this prospectus entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the related notes included elsewhere in this prospectus. Unless the context otherwise requires, references in this prospectus to the “Company,” “Regentis,” “we,” “us,” “our” and other similar designations refer to Regentis Biomaterials Ltd.

Company Overview

We are a regenerative medicine
company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of
patients. Our current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to
regenerate damaged or diseased tissue. Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue
engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Our lead product
candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries
to articular knee cartilage. GelrinC was approved as a device, with a Conformité Européene, or CE, mark in Europe, in 2017
(number 3900600CE02); we plan to identify strategic partners in Europe to bring our product to market. While we currently do not have
any strategic partners in place in Europe, we plan to engage strategic partners in Europe in the future.

With GelrinC, we aim to bring
to market a product for the therapy of an unmet need for the large market of cartilage injuries in the knee. Because GelrinC serves as
an impenetrable barrier that stops cells from migrating away from the wound’s edges, we believe our product is the only product
that helps to regenerate cartilage inwards from the edges of the cell walls. Creating new contiguous tissue is not the natural, lowest
energy, alternative for cartilage cells. If such cells were left alone, they would tend to migrate and either not create new cartilage
tissue or create cartilage tissue that is fibrotic (containing an excessive deposition